Roth Capital Issues Negative Estimate for CRDL Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Stock analysts at Roth Capital lowered their Q1 2025 EPS estimates for shares of Cardiol Therapeutics in a report issued on Wednesday, April 16th. Roth Capital analyst J. Wittes now forecasts that the company will earn ($0.13) per share for the quarter, down from their previous estimate of ($0.09). The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.33) per share. Roth Capital also issued estimates for Cardiol Therapeutics' Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.52) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.57) EPS.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last posted its quarterly earnings results on Monday, March 31st. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01.

A number of other brokerages have also issued reports on CRDL. Rodman & Renshaw initiated coverage on shares of Cardiol Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $7.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a research note on Wednesday, April 16th. Finally, RODMAN&RENSHAW raised Cardiol Therapeutics to a "strong-buy" rating in a research note on Tuesday, January 28th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $8.40.

Cardiol Therapeutics Stock Up 0.0 %

Shares of NASDAQ CRDL traded up $0.00 during mid-day trading on Friday, reaching $0.99. The company had a trading volume of 87,919 shares, compared to its average volume of 381,996. The stock has a fifty day moving average of $1.06 and a two-hundred day moving average of $1.38. Cardiol Therapeutics has a 12-month low of $0.77 and a 12-month high of $3.12. The company has a market capitalization of $82.13 million, a price-to-earnings ratio of -2.55 and a beta of 1.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.49 and a current ratio of 2.49.

Institutional Trading of Cardiol Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC bought a new position in Cardiol Therapeutics in the 3rd quarter worth $29,000. Lion Street Advisors LLC grew its position in shares of Cardiol Therapeutics by 12.6% in the fourth quarter. Lion Street Advisors LLC now owns 307,666 shares of the company's stock valued at $396,000 after purchasing an additional 34,385 shares during the last quarter. Jones Financial Companies Lllp bought a new position in shares of Cardiol Therapeutics in the fourth quarter worth about $25,000. Atria Investments Inc acquired a new position in shares of Cardiol Therapeutics during the 4th quarter worth about $174,000. Finally, Tejara Capital Ltd boosted its stake in Cardiol Therapeutics by 75.9% during the 4th quarter. Tejara Capital Ltd now owns 3,115,437 shares of the company's stock valued at $3,988,000 after purchasing an additional 1,344,167 shares during the period. 12.49% of the stock is currently owned by institutional investors and hedge funds.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.